Serum interleukin-34 levels in dermatomyositis: a potential biomarker for anti-MDA5-antibody-associated interstitial lung disease
Authors' conclusion
These data suggest that IL-34 may be involved in the development of RP-ILD in anti-MDA5 antibody-positive DM. Serum IL-34 levels can serve as a potential biomarker for RP-ILD in this clinical entity.
Study context
- Population
- DM patients, incl. anti-MDA5 antibody-positive DM; serum IL-34 measured by ELISA
- Participants
- 56 vs 14
- Exposure
- DM patients vs age- and sex-matched healthy controls
- DMn = 56
- Healthy controlsn = 14reference
- Outcome
- Serum IL-34 levels and their association with DM-ILD
Methodological detailsage- and sex-matched healthy controls, pre- and post-treatment comparison
- Age- and sex-matched healthy controls
- Pre- and post-treatment comparison
Main finding
As reported in the abstract
Serum IL-34 levels
- Serum IL-34 significantly elevated in DM patients, especially anti-MDA5 antibody-positive, vs healthy controls
Observational data: associations, not effects.
Further findings
Correlations in anti-MDA5 antibody-positive DM
- Serum IL-34 positively correlated with serum ferritin and anti-MDA5 antibody (known biomarkers for RP-ILD)
Serum IL-34 after combined immunosuppressive therapy (7 anti-MDA5 antibody-positive DM patients) · pre- and post-treatment
- Serum IL-34 decreased along with ferritin and anti-MDA5 antibody
Original publication
Serum interleukin-34 levels in dermatomyositis: a potential biomarker for anti-MDA5-antibody-associated interstitial lung disease. Rheumatology (Oxford). Published 3 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →